BridgeBio Pharma, Inc.
BBIONasdaq
$81.38
↑ +1.3%Jul 17 close · end-of-day
Price
1Y↑ +72.8%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$15.9B
Enterprise Value
$17.6B
P/E
—
P/S
27.3
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
-2.8%
Dividend Yield
—
Revenue (TTM)
$580.0M
Net Income (TTM)
—
Free Cash Flow (TTM)
-$445.1M
Gross Margin
—
Operating Margin
-90.5%
Net Margin
—
ROE
—
ROIC
—
Debt / Equity
-1.2
Net Cash
-$1.7B
Return 1Y
+74.1%
Company profile
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a stabilizer of transthyretin, or TTR.
- CEO
- Neil Kumar
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 400
- Headquarters
- California
- Website
- bridgebio.com
Management & directors
- Kumar NeilChief Executive Officer
- Trimarchi ThomasPresident and CFO
- Apuli MaricelChief Accounting Officer
Roles derived from SEC Form 4 filings.
Earnings
BBIO Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$194.5M↑ +66.8%
Diluted EPS-$0.84↓ -4.5%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $8.2M | $69.7M | $77.6M | $9.3M | $221.9M | $502.1M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$474.5M | -$576.6M | -$512.2M | -$607.4M | -$593.0M | -$523.4M |
| Net income | — | — | — | — | — | — |
| Diluted EPS | -$3.80 | -$3.90 | -$3.26 | -$3.95 | -$2.88 | -$3.78 |
| Operating cash flow | -$399.7M | -$497.9M | -$419.5M | -$527.7M | -$520.7M | -$445.9M |
| Free cash flow | -$407.2M | -$511.2M | -$424.3M | -$529.0M | -$521.7M | -$447.0M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -5752.0% | -827.1% | -659.6% | -6528.8% | -267.2% | -104.2% |
| Net margin | — | — | — | — | — | — |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.2M | $2.7M | $5.9M | $116.6M | $110.6M | $120.7M | $154.2M | $194.5M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$175.5M | -$191.8M | -$226.0M | -$104.4M | -$134.3M | -$145.2M | -$139.6M | -$106.0M |
| Net income | — | — | — | — | — | — | — | — |
| Diluted EPS | -$0.39 | -$0.86 | -$1.43 | -$0.88 | -$0.95 | -$0.95 | -$1.00 | -$0.84 |
| Operating cash flow | $74.7M | -$180.6M | -$195.3M | -$199.2M | -$80.7M | -$109.6M | -$56.4M | -$197.3M |
| Free cash flow | $74.6M | -$180.7M | -$195.4M | -$199.2M | -$81.3M | -$110.0M | -$56.5M | -$197.3M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -8096.8% | -7018.7% | -3842.7% | -89.5% | -121.4% | -120.3% | -90.5% | -54.5% |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Jul 17, 2026
Jul 13, 2026
Jul 10, 2026
- 10d agoBridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)finance.yahoo.com
- 10d agoHow a Rival's Clinical Setback Sent BBIO Stock to a 52-Week Highfinance.yahoo.com
- 10d agoBeyond The Breakout Drug: Is BridgeBio Pharma Stock A Buy On Its Next Act?trefis.com
- 10d agoBridgeBio Pharma (BBIO) Is Up 16.8% After Phase 3 Infigratinib Win And $934M Raisefinance.yahoo.com
- 10d agoBridgeBio Pharma (BBIO) Moves 15.1% Higher: Will This Strength Last?finance.yahoo.com
Jul 9, 2026
- 10d agoBridgeBio stock jumps after rival heart drug fails key trialthestreet.com
- 11d agoWhy AstraZeneca Crashed 6%, Leading Two Rivals, Including Pfizer, To Jumpfinance.yahoo.com
- 11d agoBBIO Stock Surges 16% As AstraZeneca-Ionis Heart Drug Trial Misses Goal — BofA Calls Failure ‘A Big Surprise’stocktwits.com
- 11d agoAstraZeneca and Ionis Stocks Sink on Trial Miss—Maybe Too Muchfinance.yahoo.com
- 11d agoWhy AstraZeneca Crashed 8%, Leading Three Rivals, Including Pfizer, To Jumpfinance.yahoo.com
- 11d agoIs BridgeBio Pharma (BBIO) Trading At A Premium Already?finance.yahoo.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-09 | Cook Jennifer E. | Sale | 112,422 | $90.00 | $10.1M | filing |
| 2026-07-09 | Cook Jennifer E. | Option exercise | 112,422 | $29.00 | $3.3M | filing |
| 2026-07-09 | Cook Jennifer E. | Sale | 36,167 | $84.00 | $3.0M | filing |
| 2026-07-09 | Ellis Andrea | Sale | 17,167 | $84.00 | $1.4M | filing |
| 2026-07-09 | Ellis Andrea | Option exercise | 17,167 | $16.75 | $287,547.25 | filing |
| 2026-07-09 | Cook Jennifer E. | Option exercise | 17,167 | $16.75 | $287,547.25 | filing |
| 2026-07-09 | Cook Jennifer E. | Option exercise | 19,000 | $8.45 | $160,550.00 | filing |
| 2026-06-24 | Cook Jennifer E. | Sale | 37,167 | $70.00 | $2.6M | filing |
| 2026-06-24 | Cook Jennifer E. | Option exercise | 17,167 | $16.75 | $287,547.25 | filing |
| 2026-06-24 | Cook Jennifer E. | Option exercise | 20,000 | $8.45 | $169,000.00 | filing |
| 2026-06-23 | Cook Jennifer E. | Sale | 2,196 | $68.57 | $150,579.72 | filing |
| 2026-06-23 | Valantine Hannah | Sale | 2,196 | $68.57 | $150,579.72 | filing |
| 2026-06-22 | Valantine Hannah | Sale | 2,808 | $68.00 | $190,944.00 | filing |
| 2026-06-22 | Valantine Hannah | Option exercise | 2,808 | $41.73 | $117,177.84 | filing |
| 2026-06-22 | Satvat Ali J. | Award | 3,990 | $0.00 | $0.00 | filing |
| 2026-06-22 | Cook Jennifer E. | Award | 3,990 | $0.00 | $0.00 | filing |
| 2026-06-22 | Valantine Hannah | Award | 3,990 | $0.00 | $0.00 | filing |
| 2026-06-22 | Lo Andrew | Award | 3,990 | $0.00 | $0.00 | filing |
| 2026-06-22 | HOMCY CHARLES J | Award | 3,990 | $0.00 | $0.00 | filing |
| 2026-06-22 | AGUIAR ERIC | Award | 3,990 | $0.00 | $0.00 | filing |
| 2026-06-22 | DANIELS RONALD J | Award | 3,990 | $0.00 | $0.00 | filing |
| 2026-06-22 | Ellis Andrea | Award | 3,990 | $0.00 | $0.00 | filing |
| 2026-06-22 | Hassan Fred | Award | 3,990 | $0.00 | $0.00 | filing |
| 2026-06-22 | MOMTAZEE JAMES C | Award | 3,990 | $0.00 | $0.00 | filing |
| 2026-06-22 | MCCORMICK FRANK | Award | 3,990 | $0.00 | $0.00 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.